[144] Supernus Pharmaceuticals, Inc. SEC Filing
Form 144 Notice: The filing reports a proposed sale of 4,588 shares of common stock of Supernus Pharmaceuticals, Inc. (SUPN) through Morgan Stanley Smith Barney, with an aggregate market value of $205,909.44. The shares represent part of a holding originally acquired on 05/01/2012 as an in-kind distribution from NEA Partners.
The filer for whose account sales are reported is identified as Charles Newhall, who also sold 1,412 shares on 08/22/2025 for gross proceeds of $63,543.95. The issuer's total shares outstanding are listed as 56,073,088. The notice includes the standard representation that the seller is not aware of any undisclosed material adverse information about the issuer.
Avviso Modulo 144: La comunicazione segnala la proposta di vendita di 4.588 azioni ordinarie di Supernus Pharmaceuticals, Inc. (SUPN) tramite Morgan Stanley Smith Barney, per un valore complessivo di mercato di $205.909,44. Le azioni fanno parte di una partecipazione originariamente ricevuta in data 05/01/2012 come distribuzione in natura da NEA Partners.
Il dichiarante per conto del quale sono riportate le vendite 猫 indicato come Charles Newhall, che ha anche venduto 1.412 azioni il 22/08/2025 per proventi lordi di $63.543,95. Il numero totale di azioni in circolazione dell'emittente 猫 indicato in 56.073.088. L'avviso riporta la consueta dichiarazione che il venditore non 猫 a conoscenza di informazioni negative materiali non divulgate sull'emittente.
Aviso Formulario 144: El documento informa sobre la propuesta de venta de 4.588 acciones ordinarias de Supernus Pharmaceuticals, Inc. (SUPN) a trav茅s de Morgan Stanley Smith Barney, con un valor de mercado agregado de $205.909,44. Las acciones forman parte de una tenencia originalmente adquirida el 05/01/2012 como una distribuci贸n en especie de NEA Partners.
El declarante a cuyo favor se informan las ventas se identifica como Charles Newhall, quien adem谩s vendi贸 1.412 acciones el 22/08/2025 por ingresos brutos de $63.543,95. Las acciones totales en circulaci贸n del emisor se enumeran en 56.073.088. El aviso incluye la habitual manifestaci贸n de que el vendedor no conoce informaci贸n adversa material no divulgada sobre el emisor.
靹滌嫕 144 韱奠: 鞚� 氤搓碃靹滊姅 Morgan Stanley Smith Barney毳� 韱淀暣 Supernus Pharmaceuticals, Inc.(SUPN)鞚� 氤错喌欤� 4,588欤� 毵り皝 鞝滌晥鞚� 氤搓碃頃橂┌, 齑� 鞁滉皜 臧�旃橂姅 $205,909.44鞛呺媹雼�. 頃措嫻 欤检嫕鞚� 鞗愲灅 2012-05-01鞐� NEA Partners搿滊秬韯办潣 順勲 氚半秳(鞚胳勾鞚� 氚绊彫)鞙茧 旆摑頃� 歆�攵勳潣 鞚茧秬鞛呺媹雼�.
毵り皝鞚� 氤搓碃霅� 瓿勳爼鞚� 鞁犼碃鞚胳潃 Charles Newhall搿� 旮办灛霅橃柎 鞛堨溂氅�, 攴鸽姅 霕愴暅 2025-08-22鞐� 1,412欤茧ゼ 毵り皝頃� 齑� 靾橃澋 $63,543.95毳� 鞏混棃鞀惦媹雼�. 氚滍枆須岇偓鞚� 齑� 鞙犿喌欤检嫕 靾橂姅 56,073,088欤茧 旮办灛霅橃柎 鞛堨姷雼堧嫟. 韱奠氍胳棎電� 韺愲Г鞛愱皜 氚滍枆須岇偓鞐� 雽�頃� 氙戈车臧滊悳 欷戨寑頃� 攵堧Μ頃� 鞝曤炒毳� 鞎岅碃 鞛堨 鞎婋嫟電� 響滌 歆勳垹鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟.
Avis Formulaire 144 : Le d茅p么t signale une proposition de vente de 4 588 actions ordinaires de Supernus Pharmaceuticals, Inc. (SUPN) via Morgan Stanley Smith Barney, pour une valeur de march茅 totale de 205 909,44 $. Les actions font partie d鈥檜ne d茅tention initialement acquise le 05/01/2012 sous forme de distribution en nature de NEA Partners.
Le d茅clarant pour le compte duquel les ventes sont rapport茅es est identifi茅 comme Charles Newhall, qui a 茅galement vendu 1 412 actions le 22/08/2025 pour un produit brut de 63 543,95 $. Le nombre total d鈥檃ctions en circulation de l鈥櫭﹎etteur est indiqu茅 脿 56 073 088. L鈥檃vis comprend la mention habituelle selon laquelle le vendeur n鈥檃 connaissance d鈥檃ucune information d茅favorable mat茅rielle non divulgu茅e concernant l鈥櫭﹎etteur.
Formular 144-Mitteilung: Die Meldung berichtet 眉ber den geplanten Verkauf von 4.588 Stammaktien von Supernus Pharmaceuticals, Inc. (SUPN) 眉ber Morgan Stanley Smith Barney mit einem kumulierten Marktwert von $205.909,44. Die Aktien stammen aus einem Bestand, der urspr眉nglich am 05/01/2012 als Sachdividende von NEA Partners erworben wurde.
Der Meldende, f眉r dessen Konto die Verk盲ufe angegeben sind, wird als Charles Newhall genannt, der au脽erdem am 22.08.2025 1.412 Aktien verkaufte und Bruttoerl枚se von $63.543,95 erzielte. Die insgesamt ausgegebenen Aktien des Emittenten werden mit 56.073.088 angegeben. Die Mitteilung enth盲lt die 眉bliche Angabe, dass der Ver盲u脽erer keine Kenntnis von nicht offengelegten, wesentlichen nachteiligen Informationen 眉ber den Emittenten hat.
- None.
- None.
Insights
TL;DR: Small insider sale relative to shares outstanding; not likely material to SUPN's valuation.
The filing shows a planned sale of 4,588 common shares valued at $205,909.44 and a recent 10b5-1 sale of 1,412 shares for $63,543.95. Given the issuer's reported 56,073,088 shares outstanding, the transaction size is trivial as a percentage of the float. The acquisition origin (in-kind distribution from NEA Partners in 2012) is disclosed, which is relevant for lock-up/holding-period context. There is no new operational or financial information in the notice; it is a standard reporting of intended insider dispositions.
TL;DR: Routine insider disclosure consistent with Rule 144; includes representation about nonpublic material information.
The notice follows Rule 144 disclosure conventions and names the broker and planned sale date. The seller attests not to possess undisclosed material adverse information, and the filing references prior 10b5-1 sales activity. From a governance standpoint, this is a compliance disclosure rather than a signal of corporate change. No departures, new plans, or control transactions are reported.
Avviso Modulo 144: La comunicazione segnala la proposta di vendita di 4.588 azioni ordinarie di Supernus Pharmaceuticals, Inc. (SUPN) tramite Morgan Stanley Smith Barney, per un valore complessivo di mercato di $205.909,44. Le azioni fanno parte di una partecipazione originariamente ricevuta in data 05/01/2012 come distribuzione in natura da NEA Partners.
Il dichiarante per conto del quale sono riportate le vendite 猫 indicato come Charles Newhall, che ha anche venduto 1.412 azioni il 22/08/2025 per proventi lordi di $63.543,95. Il numero totale di azioni in circolazione dell'emittente 猫 indicato in 56.073.088. L'avviso riporta la consueta dichiarazione che il venditore non 猫 a conoscenza di informazioni negative materiali non divulgate sull'emittente.
Aviso Formulario 144: El documento informa sobre la propuesta de venta de 4.588 acciones ordinarias de Supernus Pharmaceuticals, Inc. (SUPN) a trav茅s de Morgan Stanley Smith Barney, con un valor de mercado agregado de $205.909,44. Las acciones forman parte de una tenencia originalmente adquirida el 05/01/2012 como una distribuci贸n en especie de NEA Partners.
El declarante a cuyo favor se informan las ventas se identifica como Charles Newhall, quien adem谩s vendi贸 1.412 acciones el 22/08/2025 por ingresos brutos de $63.543,95. Las acciones totales en circulaci贸n del emisor se enumeran en 56.073.088. El aviso incluye la habitual manifestaci贸n de que el vendedor no conoce informaci贸n adversa material no divulgada sobre el emisor.
靹滌嫕 144 韱奠: 鞚� 氤搓碃靹滊姅 Morgan Stanley Smith Barney毳� 韱淀暣 Supernus Pharmaceuticals, Inc.(SUPN)鞚� 氤错喌欤� 4,588欤� 毵り皝 鞝滌晥鞚� 氤搓碃頃橂┌, 齑� 鞁滉皜 臧�旃橂姅 $205,909.44鞛呺媹雼�. 頃措嫻 欤检嫕鞚� 鞗愲灅 2012-05-01鞐� NEA Partners搿滊秬韯办潣 順勲 氚半秳(鞚胳勾鞚� 氚绊彫)鞙茧 旆摑頃� 歆�攵勳潣 鞚茧秬鞛呺媹雼�.
毵り皝鞚� 氤搓碃霅� 瓿勳爼鞚� 鞁犼碃鞚胳潃 Charles Newhall搿� 旮办灛霅橃柎 鞛堨溂氅�, 攴鸽姅 霕愴暅 2025-08-22鞐� 1,412欤茧ゼ 毵り皝頃� 齑� 靾橃澋 $63,543.95毳� 鞏混棃鞀惦媹雼�. 氚滍枆須岇偓鞚� 齑� 鞙犿喌欤检嫕 靾橂姅 56,073,088欤茧 旮办灛霅橃柎 鞛堨姷雼堧嫟. 韱奠氍胳棎電� 韺愲Г鞛愱皜 氚滍枆須岇偓鞐� 雽�頃� 氙戈车臧滊悳 欷戨寑頃� 攵堧Μ頃� 鞝曤炒毳� 鞎岅碃 鞛堨 鞎婋嫟電� 響滌 歆勳垹鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟.
Avis Formulaire 144 : Le d茅p么t signale une proposition de vente de 4 588 actions ordinaires de Supernus Pharmaceuticals, Inc. (SUPN) via Morgan Stanley Smith Barney, pour une valeur de march茅 totale de 205 909,44 $. Les actions font partie d鈥檜ne d茅tention initialement acquise le 05/01/2012 sous forme de distribution en nature de NEA Partners.
Le d茅clarant pour le compte duquel les ventes sont rapport茅es est identifi茅 comme Charles Newhall, qui a 茅galement vendu 1 412 actions le 22/08/2025 pour un produit brut de 63 543,95 $. Le nombre total d鈥檃ctions en circulation de l鈥櫭﹎etteur est indiqu茅 脿 56 073 088. L鈥檃vis comprend la mention habituelle selon laquelle le vendeur n鈥檃 connaissance d鈥檃ucune information d茅favorable mat茅rielle non divulgu茅e concernant l鈥櫭﹎etteur.
Formular 144-Mitteilung: Die Meldung berichtet 眉ber den geplanten Verkauf von 4.588 Stammaktien von Supernus Pharmaceuticals, Inc. (SUPN) 眉ber Morgan Stanley Smith Barney mit einem kumulierten Marktwert von $205.909,44. Die Aktien stammen aus einem Bestand, der urspr眉nglich am 05/01/2012 als Sachdividende von NEA Partners erworben wurde.
Der Meldende, f眉r dessen Konto die Verk盲ufe angegeben sind, wird als Charles Newhall genannt, der au脽erdem am 22.08.2025 1.412 Aktien verkaufte und Bruttoerl枚se von $63.543,95 erzielte. Die insgesamt ausgegebenen Aktien des Emittenten werden mit 56.073.088 angegeben. Die Mitteilung enth盲lt die 眉bliche Angabe, dass der Ver盲u脽erer keine Kenntnis von nicht offengelegten, wesentlichen nachteiligen Informationen 眉ber den Emittenten hat.
FAQ
What securities does the SUPN Form 144 report propose to sell?
What is the aggregate market value of the shares to be sold under the SUPN Form 144?
Who is the person for whose account the SUPN securities are being sold?
How were the shares being sold originally acquired?
Does the Form 144 indicate any undisclosed material information about SUPN?
